EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Childhood Refractory Autoimmune Haemolitic Anaemia with Mabthera



Treatment of Childhood Refractory Autoimmune Haemolitic Anaemia with Mabthera



Blood 100(11): Abstract No 3479, November 16



Autoimmune haemolitic anaemia commonly has a severe course in young children, thus requiring multiple immunosuppressive treatments. One child with refractory idiopathic autoimmune haemolitic anaemia, was treated with mabthera, a monoclonal antibody against CD20. Tolerance of the treatment was good. However, circulating B cells were absent. The patient remained in complete remission 15 months after start of mabthera therapy. Corticosteroids and immunosuppressive drugs had their doses reduced and were stopped after the mabthera administration. We suggest that mabthera could be a valuable treatment for autoimmune haemolitic anemia, although a long-lasting but transient B-cell deficiency develops.

(PDF 0-2 workdays service: $29.90)

Accession: 035980365

Download citation: RISBibTeXText



Related references

Refractory autoimmune haemolytic anaemia in childhood Is there a role for Rituximab?. British Journal of Haematology 113(Supplement 1): 45, 2001

Childhood refractory autoimmune haemolytic anaemia: is there a role for anti-CD20 therapy (rituximab)?. British Journal of Haematology 117(2): 480-483, 2002

Danazol for treatment of refractory autoimmune hemolytic anaemia. Annals of the Academy of Medicine, Singapore 18(6): 707-709, 1989

Successful treatment of refractory autoimmune haemolytic anaemia by plasmapheresis. Scandinavian Journal of Haematology 32(2): 149-152, 1984

Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). British Journal of Haematology 114(1): 244-245, 2001

Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet (North American Edition) 358(9292): 1511-1513, November 3, 2001

Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant. Archives of Disease in Childhood 88(4): 337-339, 2003

Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anaemia associated with idiopathic membranous nephropathy. Rheumatology 44(3): 403-405, 2005

Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplantation 29(10): 871-872, 2002

Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders. Harefuah 151(10): 562-5, 606, 2013

Durable remission after Mabthera treatment for refractory idiopathic cold haemagglutinin disease. British Journal of Haematology 113(Supplement 1): 41, 2001

A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy. Voprosy Onkologii 50(4): 421-425, 2004

The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia. Farmacia Hospitalaria 31(2): 124-127, 2007